Vistagen Therapeutics Inc share price logo

Vistagen Therapeutics Inc Share Price

NASDAQ: VTGN

Small Cap

$3.25

-0.14

(-4.27%)

as on

Vistagen Therapeutics Inc Stock Performance

as on September 16, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $3.23
    $3.5
    downward going graph

    0.62%

    Downside

    7.69%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.9
    $3.88
    downward going graph

    41.54%

    Downside

    19.38%

    Upside

    downward going graph

Vistagen Therapeutics Inc share price movements today

Previous Close
$3.39
Open
$3.44
Volume
604.9K
Day's Low - High
$3.23 - $3.5
52 Week Low - High
$1.9 - $3.88

Vistagen Therapeutics Inc Historical Returns

1 Month Return
+ 2.42 %
3 Month Return
+ 53.39 %
1 Year Return
+ 3.04 %
3 Year Return
-41.05 %
5 Year Return
-82.66 %

Vistagen Therapeutics Inc Stock Fundamentals & Key Indicators

Check Vistagen Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$104.0M

EPS (TTM)

-1.735

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-59.5M

Revenue (TTM)

646.0K

Profit Margin

0.00%

Return On Equity TTM

289600.00%

Vistagen Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Vistagen Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Vistagen Therapeutics Inc image
Vistagen Therapeutics Inc
BUY$104.0M-82.66%NA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$61.1B256.98%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$38.7BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$101.1B47.85%28.0731.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$59.4B-3.43%14.1131.37%

Stock Returns calculator for Vistagen Therapeutics Inc Stock including INR - Dollar returns

The Vistagen Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Vistagen Therapeutics Inc investment value today

Current value as on today

₹1,03,770

Returns

₹3,770

(+3.77%)

Returns from Vistagen Therapeutics Inc Stock

₹1,216 (-1.22%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on Vistagen Therapeutics Inc Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Vistagen Therapeutics Inc. Average target price of $14.5

Vistagen Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Vistagen Therapeutics Inc.

What analysts predicted

77.59%UPSIDE

Target Price

$14.5

Current Price

$3.25

Analyzed by

10 Analysts

Target

$14.50

Vistagen Therapeutics Inc target price $14.5, a slight upside of 77.59% compared to current price of $3.25. According to 10 analysts rating.

Vistagen Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-12
-6
-6
-7
-11
-12
-14
-15
-14
-15
EBITDA
-12
-6
-6
-7
-11
-11
-14
-14
-14
-14
Interest Expense
0
0
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-12
-6
-6
-6
-9
-10
-12
-14
-13
-15
Income Tax Expense
0
0
0
1,532
0
0
0
-14
-
-
Net Income
-12
-6
-6
-6
-9
-10
-12
-14
-13
-15
Net Profit Margin
-6962.98%
-3900.00%
-2369.78%
-1543.46%
-4825.85%
-12777.38%
-7082.51%
-6020.94%
90900.00%
-6186.48%

Vistagen Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Total Revenue
-
1
-
-
0
1
1
0
1
0
Gross Profit
-
1
-
0
0
1
1
0
1
0
Operating Income
-17
-10
-14
-24
-20
-17
-47
-59
-33
-55
EBITDA
-17
-9
-14
-24
-20
-17
-47
-58
-32
-55
Interest Expense
0
0
0
0
0
0
0
0
-
-
Depreciation
-
-
0
0
0
0
0
0
0
0
Income Before Tax
-47
-10
-14
-24
-20
-17
-47
-59
-29
-51
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-47
-10
-14
-24
-20
-17
-47
-59
-29
-51
Net Profit Margin
0.00%
-820.44%
0.00%
0.00%
-6219.76%
-1646.09%
-4307.19%
26065.86%
-2759.59%
-10579.84%

Vistagen Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-6
-6
-6
-9
-10
-12
-14
-13
-15
Operating Cash Flow
-7
-6
-4
-7
-10
-10
-10
-10
-18
Investing Cash Flow
-
-
0
0
-5
-7
0
0
0
Financing Cash Flow
0
34
93
0
0
-
1
1
1
Change in Cash
-7
27
88
-7
-16
-18
-9
-7
-18

Vistagen Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Income
-10
-14
-24
-20
-17
-47
-59
-29
-51
Operating Cash Flow
-7
-9
-14
-15
-12
-45
-49
-25
-42
Investing Cash Flow
0
0
0
0
0
0
0
0
-13
Financing Cash Flow
9
16
17
4
114
10
-1
128
3
Change in Cash
2
7
2
-11
101
-34
-51
102
-52

Global Institutional Holdings in Vistagen Therapeutics Inc

Funds
Holdings
TCG Crossover Management, LLC
8.96%
StemPoint Capital LP
7.93%
Nantahala Capital Management, LLC
6.63%
Vanguard Group Inc
6.56%
COMMODORE CAPITAL LP
5.27%
See all

Insights on Vistagen Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, -15.0K → 244.0K (in $), with an average increase of 106.2% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, VTGN stock has moved up by 53.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 123.5% return, outperforming this stock by 164.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.6% return, outperforming this stock by 72.6%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -13.63M → -15.09M (in $), with an average decrease of 10.7% per quarter

About Vistagen Therapeutics Inc

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
OrganisationVistagen Therapeutics Inc
Headquarters343 Allerton Avenue, South San Francisco, CA, United States, 94080
IndustryHealth Technology
CEOMr. Shawn K. Singh J.D.
E-voting on sharesClick here to vote

Key Management of Vistagen Therapeutics Inc

Name

Title

Dr. Mark J. Ginski Ph.D.

Senior VP and Head of Chemistry, Manufacturing & Controls

Ms. Cynthia Lynn Anderson CPA

VP & Chief Financial Officer

Mr. Joshua S. Prince M.B.A.

Chief Operating Officer

Mr. Reid G. Adler Esq., J.D.

Chief Legal Officer

Mr. Mark Adrian McPartland

Senior Vice President of Investor Relations

Ms. Michelle Peters Wellington

Vice President of Communications

Ms. Trisha Fitzmaurice

Senior Vice President of Human Resources

Dr. Allen Easley Cato III, M.D., Ph.D.

Senior Vice President of Development Operations

Mr. Shawn K. Singh J.D.

President, CEO & Director

Ms. Elissa Cote

Chief Corporate Development Officer

FAQs

What is Vistagen Therapeutics Inc share price today?

Vistagen Therapeutics Inc share price today is $3.25 as on at the close of the market. Vistagen Therapeutics Inc share today touched a day high of $3.5 and a low of $3.23.

What is the 52 week high and 52 week low for Vistagen Therapeutics Inc share?

Vistagen Therapeutics Inc share touched a 52 week high of $3.88 on and a 52 week low of $1.9 on . Vistagen Therapeutics Inc stock price today i.e. is closed at $3.25,which is 16.24% down from its 52 week high and 71.05% up from its 52 week low.

What is Vistagen Therapeutics Inc's market capitalisation today?

Vistagen Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Vistagen Therapeutics Inc Stock (VTGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Vistagen Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vistagen Therapeutics Inc Shares that will get you 0.4615 shares as per Vistagen Therapeutics Inc share price of $3.25 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Vistagen Therapeutics Inc Stock (VTGN) from India?

Indian investors can start investing in Vistagen Therapeutics Inc (VTGN) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Vistagen Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Vistagen Therapeutics Inc share’s latest price of $3.25 as on September 16, 2025 at 1:29 am IST, you will get 3.0769 shares of Vistagen Therapeutics Inc. Learn more about fractional shares .

What are the returns that Vistagen Therapeutics Inc has given to Indian investors in the last 5 years?

Vistagen Therapeutics Inc stock has given -82.66% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?